Inventiva: €230M in Cash but Less Than a Year of Financial Autonomy
The French biotech company reports its 2025 results with a record cash position thanks to two major fundraising events. However, accelerated cash burn and lack of commercial revenues reduce the company's financial autonomy to less than a year, ahead of the expected results of its flagship treatment for MASH in the fourth quarter of 2026.
Financial Position and Fundraising Achievements
Inventiva closed the fiscal year 2025 with €99.3 million in cash and €131.6 million in short-term deposits, bringing its liquid resources to €230.9 million. This accumulation resulted from two major financing operations: the release of €115.6 million gross (€108.0 million net) in May 2025 as part of a structured financing announced in October 2024, and a capital raise of $172.5 million (€139.4 million net) conducted on the New York Stock Exchange in November 2025. In total, cash flows from financing reached €241.3 million in 2025, compared to €145.6 million in 2024. This increase reflects Inventiva’s determination to secure its resources ahead of the key publication of its NATiV3 pivotal clinical trial results.
Operational Cash Burn and Revenue Challenges
Despite strengthening its cash portfolio, Inventiva sees its operational cash gap widening. The net cash consumption related to operational activities reached €104.9 million in 2025, up from €85.9 million in 2024, an increase of 22%. This acceleration is due to three factors: the net impact of the strategic reorganization plan implemented in 2025, the drop in revenues from the licensing agreement with CTTQ, and the increase in administrative expenses to €47.9 million (from €15.8 million in 2024), including €20.3 million in stock-based compensation. Concurrently, revenue plummeted to €4.5 million in 2025 from €9.2 million in 2024, while investments in marketing and commercial development jumped to €5.0 million (from €2.0 million in 2024), in preparation for a potential commercial launch.
Future Prospects and Strategic Adjustments
At the current rate of expenditure, Inventiva estimates that its cash and liquidity will fund its operations until the middle of the first quarter of 2027. This timeline perhaps explains why the group has adjusted its schedule for publishing the results of NATiV3 to the fourth quarter of 2026, in order to maximize its chances of quickly obtaining regulatory approval or securing strategic partnerships. CEO Andrew Obenshain assures that the regulatory and commercial infrastructure is 'progressing in parallel' to act 'swiftly' once the data is available. If the warrants for tranche 3 of the structured financing are fully exercised, Inventiva could generate an additional €116.0 million, extending its autonomy until the middle of the third quarter of 2027. However, there is no guarantee that these warrants will be exercised. For investors, the suspense remains: Inventiva must turn the NATiV3 trial into a commercial success before the countdown becomes critical.
